A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
NRG Oncology
Pfizer
Shanghai Henlius Biotech
Exelixis
The Netherlands Cancer Institute
Neonc Technologies, Inc.
Peking Union Medical College Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Maastricht University Medical Center
Abramson Cancer Center at Penn Medicine
IFOM ETS - The AIRC Institute of Molecular Oncology
Odense University Hospital
GERCOR - Multidisciplinary Oncology Cooperative Group
University of California, Irvine
Gustave Roussy, Cancer Campus, Grand Paris
Second Affiliated Hospital of Guangzhou Medical University
Persephone Biosciences